Dagmara Hering

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9407387/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet, The, 2016, 388, 2665-2712.	13.7	670
2	Substantial Reduction in Single Sympathetic Nerve Firing After Renal Denervation in Patients With Resistant Hypertension. Hypertension, 2013, 61, 457-464.	2.7	331
3	Renal Denervation in Moderate to Severe CKD. Journal of the American Society of Nephrology: JASN, 2012, 23, 1250-1257.	6.1	322
4	Gender-Selective Interaction Between Aging, Blood Pressure, and Sympathetic Nerve Activity. Hypertension, 2005, 45, 522-525.	2.7	304
5	An independent relationship between muscle sympathetic nerve activity and pulse wave velocity in normal humans. Journal of Hypertension, 2010, 28, 979-984.	0.5	136
6	Non-dipping pattern of hypertension and obstructive sleep apnea syndrome. Hypertension Research, 2010, 33, 867-871.	2.7	133
7	Sustained Sympathetic and Blood Pressure Reduction 1 Year After Renal Denervation in Patients With Resistant Hypertension. Hypertension, 2014, 64, 118-124.	2.7	132
8	International Expert Consensus Statement. Journal of the American College of Cardiology, 2013, 62, 2031-2045.	2.8	124
9	Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. International Journal of Cardiology, 2013, 168, 2214-2220.	1.7	122
10	Unilateral Carotid Body Resection inÂResistant Hypertension. JACC Basic To Translational Science, 2016, 1, 313-324.	4.1	118
11	Hypertension and cognitive dysfunction in elderly: blood pressure management for this global burden. BMC Cardiovascular Disorders, 2016, 16, 208.	1.7	99
12	Sympathetic Neural Outflow and Chemoreflex Sensitivity Are Related to Spontaneous Breathing Rate in Normal Men. Hypertension, 2006, 47, 51-55.	2.7	89
13	Role of the Sympathetic Nervous System in Stress-Mediated Cardiovascular Disease. Current Hypertension Reports, 2015, 17, 80.	3.5	82
14	TMA, A Forgotten Uremic Toxin, but Not TMAO, Is Involved in Cardiovascular Pathology. Toxins, 2019, 11, 490.	3.4	81
15	Health-Related Quality of Life After Renal Denervation in Patients With Treatment-Resistant Hypertension. Hypertension, 2012, 60, 1479-1484.	2.7	72
16	Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure. Journal of Hypertension, 2007, 25, 157-161.	0.5	68
17	Effects of Renal Denervation on Sympathetic Activation, Blood Pressure, and Glucose Metabolism in Patients with Resistant Hypertension. Frontiers in Physiology, 2012, 3, 10.	2.8	67
18	Renal nerve ablation reduces augmentation index in patients with resistant hypertension. Journal of Hypertension, 2013, 31, 1893-1900.	0.5	66

#	Article	IF	CITATIONS
19	Revelations About Carotid Body Function Through its Pathological Role in Resistant Hypertension. Current Hypertension Reports, 2013, 15, 273-280.	3.5	62
20	Renal Denervation Reduces Monocyte Activation and Monocyte–Platelet Aggregate Formation. Hypertension, 2017, 69, 323-331.	2.7	61
21	Dyslipidemia Is Associated With Sympathetic Nervous Activation and Impaired Endothelial Function in Young Females. American Journal of Hypertension, 2013, 26, 250-256.	2.0	59
22	Reverse cardiac remodeling after renal denervation: Atrial electrophysiologic and structural changes associated with blood pressure lowering. Heart Rhythm, 2015, 12, 982-990.	0.7	58
23	Effect of renal denervation on kidney function in patients with chronic kidney disease. International Journal of Cardiology, 2017, 232, 93-97.	1.7	56
24	Influences of Gender on the Interaction between Sympathetic Nerve Traffic and Central Adiposity. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4974-4978.	3.6	50
25	Smoking is associated with chronic sympathetic activation in hypertension. Blood Pressure, 2010, 19, 152-155.	1.5	47
26	Sympathetic Response and Outcomes Following Renal Denervation in Patients With Chronic Heart Failure: 12-Month Outcomes From the Symplicity HF Feasibility Study. Journal of Cardiac Failure, 2017, 23, 702-707.	1.7	44
27	Renal Denervation in Human Hypertension: Mechanisms, Current Findings, and Future Prospects. Current Hypertension Reports, 2012, 14, 247-253.	3.5	43
28	Effects of acute and long-term slow breathing exercise on muscle sympathetic nerve activity in untreated male patients with hypertension. Journal of Hypertension, 2013, 31, 739-746.	0.5	42
29	High-normal blood pressure is associated with increased resting sympathetic activity but normal responses to stress tests. Blood Pressure, 2013, 22, 183-187.	1.5	38
30	A polymorphism in the norepinephrine transporter gene is associated with affective and cardiovascular disease through a microRNA mechanism. Molecular Psychiatry, 2017, 22, 134-141.	7.9	38
31	Routine assessment of cognitive function in older patients with hypertension seen by primary care physicians: why and how—a decision-making support from the working group on †hypertension and the brain' of the European Society of Hypertension and from the European Geriatric Medicine Society.	0.5	30
32	The influence of chemotherapy on the right ventricle: did we forget something?. Clinical Cardiology, 2017, 40, 437-443.	1.8	29
33	Resting sympathetic outflow does not predict the morning blood pressure surge in hypertension. Journal of Hypertension, 2011, 29, 2381-2386.	0.5	27
34	The Role of Central Nervous System Mechanisms in Resistant Hypertension. Current Hypertension Reports, 2015, 17, 58.	3.5	26
35	Ambulatory arterial stiffness index as a predictor of blood pressure response to renal denervation*. Journal of Hypertension, 2018, 36, 1414-1422.	0.5	26
36	Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation. EuroIntervention, 2013, 9, R127-R135.	3.2	26

#	Article	IF	CITATIONS
37	Renal denervation: current implications and future perspectives. Clinical Science, 2014, 126, 41-53.	4.3	24
38	Opposing effects of shear-mediated dilation and myogenic constriction on artery diameter in response to handgrip exercise in humans. Journal of Applied Physiology, 2015, 119, 858-864.	2.5	23
39	Renal denervation in hypertensive patients not on blood pressure lowering drugs. Clinical Research in Cardiology, 2016, 105, 755-762.	3.3	21
40	Radiotherapy-induced right ventricular remodelling: The missing piece of the puzzle. Archives of Cardiovascular Diseases, 2017, 110, 116-123.	1.6	21
41	Blood pressure in acute ischemic stroke. Journal of Hypertension, 2018, 36, 1212-1221.	0.5	21
42	Comparable Attenuation of Sympathetic Nervous System Activity in Obese Subjects with Normal Glucose Tolerance, Impaired Glucose Tolerance, and Treatment NaÃ ⁻ ve Type 2 Diabetes following Equivalent Weight Loss. Frontiers in Physiology, 2016, 7, 516.	2.8	20
43	Renal artery anatomy affects the blood pressure response to renal denervation in patients with resistant hypertension. International Journal of Cardiology, 2016, 202, 388-393.	1.7	20
44	R1 autonomic nervous system in acute kidney injury. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 162-171.	1.9	20
45	Sympathetic neural responses to smoking are age dependent. Journal of Hypertension, 2006, 24, 691-695.	0.5	19
46	Potentiated sympathetic and hemodynamic responses to alcohol in hypertensive vs. normotensive individuals. Journal of Hypertension, 2011, 29, 537-541.	0.5	19
47	Association of vitamin D status and blood pressure response after renal denervation. Clinical Research in Cardiology, 2014, 103, 41-47.	3.3	19
48	A polymorphism in the noradrenaline transporter gene is associated with increased blood pressure in patients with resistant hypertension. Journal of Hypertension, 2018, 36, 1571-1577.	0.5	19
49	Longitudinal tracking of muscle sympathetic nerve activity and its relationship with blood pressure in subjects with prehypertension. Blood Pressure, 2016, 25, 184-192.	1.5	17
50	Arterial Norepinephrine Concentration is Inversely and Independently Associated With Insulin Clearance in Obese Individuals With Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1544-1550.	3.6	16
51	Long-term effects of device-guided slow breathing in stable heart failure patients with reduced ejection fraction. Clinical Research in Cardiology, 2019, 108, 48-60.	3.3	16
52	Recent advances in the treatment of hypertension. Expert Review of Cardiovascular Therapy, 2011, 9, 729-744.	1.5	14
53	Recent advances in the pathophysiology of arterial hypertension - potential implications for clinical practice. Polish Archives of Internal Medicine, 2017, 127, 195-204.	0.4	14
54	Heightened acute circulatory responses to smoking in women. Blood Pressure, 2008, 17, 141-146.	1.5	13

#	Article	IF	CITATIONS
55	Reduction in peripheral vascular resistance predicts improvement in insulin clearance following weight loss. Cardiovascular Diabetology, 2015, 14, 113.	6.8	13
56	Anatomical and procedural determinants of catheter-based renal denervation. Cardiovascular Revascularization Medicine, 2016, 17, 474-479.	0.8	13
57	Successful renal denervation decreases the platelet activation status in hypertensive patients. Cardiovascular Research, 2020, 116, 202-210.	3.8	13
58	Recommendation for the management of dyslipidemia in Poland — Third Declaration of Sopot. Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. Cardiology Journal, 2018, 25, 655-665.	1.2	13
59	Drug Interactions Affecting Kidney Function: Beware of Health Threats from Triple Whammy. Advances in Therapy, 2022, 39, 140-147.	2.9	13
60	Levosimendan improves the acute course of takotsubo syndrome: a pooled analysis. ESC Heart Failure, 2021, 8, 4360-4363.	3.1	11
61	Effects of renal denervation on insulin resistance. Expert Review of Cardiovascular Therapy, 2012, 10, 1381-1386.	1.5	10
62	Blood Pressure and Sympathetic Nervous System Response to Renal Denervation. Hypertension, 2013, 61, e13.	2.7	10
63	Advances in Sympathetic Nerve Recording in Humans. Frontiers in Physiology, 2012, 3, 11.	2.8	9
64	The Effect of Renal Denervation on Plasma Adipokine Profile in Patients with Treatment Resistant Hypertension. Frontiers in Physiology, 2017, 8, 369.	2.8	9
65	Lipids, Blood Pressure, Kidney-what was New in 2012?. International Journal of Pharmacology, 2012, 8, 659-678.	0.3	9
66	Slow breathing improves cardiovascular reactivity to mental stress and health-related quality of life in heart failure patients with reduced ejection fraction. Cardiology Journal, 2020, 27, 772-779.	1.2	9
67	Sympathetic nervous system and arterial hypertension: new perspectives, new data. Kardiologia Polska, 2013, 71, 441-446.	0.6	8
68	Renal nerve ablation reduces blood pressure in a patient with renovascular hypertension resistant to drug and revascularisation therapies. International Journal of Cardiology, 2012, 159, e35-e36.	1.7	7
69	Health-related quality of life and blood pressure 12 months after renal denervation. Journal of Hypertension, 2015, 33, 2350-2358.	0.5	7
70	Central arteriovenous anastomosis in resistant hypertension?. Lancet, The, 2015, 385, 1596-1597.	13.7	7
71	Renal denervation superior to drug therapy in hypertension. Lancet, The, 2015, 385, 1922-1924.	13.7	7
72	Sympathetic Activation in Chronic Heart Failure: Potential Benefits of Interventional Therapies. Current Hypertension Reports, 2016, 18, 51.	3.5	7

#	Article	IF	CITATIONS
73	Device Therapies for Resistant Hypertension. Clinical Therapeutics, 2016, 38, 2152-2158.	2.5	7
74	Age-dependent sympathetic neural responses to ß ₁ selective beta-blockade in untreated hypertension-related tachycardia. Blood Pressure, 2018, 27, 158-165.	1.5	6
75	May Measurement Month 2017: an analysis of blood pressure screening results from Australia—South-East Asia and Australasia. European Heart Journal Supplements, 2019, 21, D14-D16.	0.1	6
76	A perspective of private health care providers in the state of Madhya Pradesh on adopting key strategies of the India hypertension control initiative. Journal of Clinical Hypertension, 2020, 22, 1321-1327.	2.0	6
77	Smoking and cardiovascular risk. Journal of Hypertension, 2004, 22, 31-34.	0.5	5
78	Central Sympathetic Inhibition: a Neglected Approach for Treatment of Cardiac Arrhythmias?. Current Hypertension Reports, 2016, 18, 13.	3.5	5
79	Soluble vascular endothelial growth factor receptor-1 is reduced in patients with resistant hypertension after renal denervation. Journal of Human Hypertension, 2017, 31, 248-252.	2.2	5
80	Repeatability and reproducibility of pulse wave velocity in relation to hemodynamics and sodium excretion in stable patients with hypertension. Journal of Hypertension, 2020, 38, 1531-1540.	0.5	5
81	Patient counselling service with the use of pictograms as the example of pharmacist intervention to improving compliance and medicine safety. Cardiology Journal, 2021, 28, 879-886.	1.2	5
82	Levosimendan: New hope therapy for takotsubo syndrome. Cardiology Journal, 2016, 23, 616-617.	1.2	5
83	Tachycardia: The hidden cardiovascular risk factor in uncomplicated arterial hypertension. Cardiology Journal, 2020, 27, 857-867.	1.2	5
84	Normalization of the Mini-MAC (Mental Adjustment to Cancer) Questionnaire among Cancer Patients. International Journal of Environmental Research and Public Health, 2021, 18, 12603.	2.6	5
85	Case of Refractory Hypertension Controlled by Repeated Renal Denervation and Celiac Plexus Block. Hypertension, 2017, 69, 978-984.	2.7	4
86	Malignancy predicts shortâ€ŧerm mortality in Takotsubo: insights from a metaâ€analysis of 125Â359 patients. ESC Heart Failure, 2021, 8, 4357-4359.	3.1	4
87	Comparison of hypertension epidemiology and treatment in Poland and Australia. Kardiologia Polska, 2018, 76, 520-528.	0.6	4
88	Management of dyslipidemia in Poland: Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. The Fourth Declaration of Sopot. Cardiology Journal, 2022, 29, 1-26.	1.2	4
89	Sympathetic neural responses to coronary occlusion during balloon angioplasty. Journal of Hypertension, 2007, 25, 1650-1654.	0.5	3
90	Residual Sympathetic Responsiveness After Catheter-Based Renal Denervation. Hypertension, 2016, 67, 1117-1118.	2.7	3

#	Article	IF	CITATIONS
91	Predictive Role of Nighttime Blood Pressure in Response to Renal Denervation. Hypertension, 2017, 69, 398-400.	2.7	3
92	Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?. Current Hypertension Reports, 2017, 19, 30.	3.5	3
93	Impact of Renal Pelvic Denervation on Systemic Hemodynamics and Neurohumoral Changes in a Porcine Model. American Journal of Nephrology, 2021, 52, 429-434.	3.1	3
94	Response to Quality of Life After Renal Denervation. Hypertension, 2013, 61, e39.	2.7	2
95	OS 28-02 RENAL DENERVATION ALTERS ADIPOKINE LEVELS IN PATIENTS WITH RESISTANT HYPERTENSION. Journal of Hypertension, 2016, 34, e251.	0.5	2
96	[OP.7A.06] FIRST-IN-HUMAN EVALUATION OF A TRANSVENOUS CAROTID BODY ABLATION DEVICE TO TREAT PATIENTS WITH RESISTANT HYPERTENSION. Journal of Hypertension, 2017, 35, e64.	0.5	2
97	Beta-2 adrenoreceptor gene polymorphisms and sympathetic outflow in humans. Clinical Autonomic Research, 2011, 21, 333-338.	2.5	1
98	Catheter based radiofrequency ablation of renal nerves for the treatment of resistant hypertension. Italian Journal of Medicine, 2012, 6, 105-109.	0.3	1
99	ISH NIA OS-01 THE microRNA miR-19a-3p BINDS TO A POLYMORPHISM IN THE GENE FOR THE NORADRENALINE TRANSPORTER AND MAY INCREASE THE RISK OF CARDIOVASCULAR AND PSYCHIATRIC DISEASE. Journal of Hypertension, 2016, 34, e42.	0.5	1
100	OS 19-01 BLOOD PRESSURE INDEPENDENT EFFECTS OF RENAL DENERVATION ON THE DECLINE OF KIDNEY FUNCTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Journal of Hypertension, 2016, 34, e228.	0.5	1
101	Renal denervation in less severe forms of (resistant) hypertension—Quo vadis?. Journal of Clinical Hypertension, 2017, 19, 369-370.	2.0	1
102	Prognostic significance of masked tachycardia in hypertension. Journal of Hypertension, 2017, 35, 468-470.	0.5	1
103	[OP.7A.11] CHROMOGRANIN A AS A PREDICTIVE MARKER OF SUCCESSFUL RENAL DENERVATION. Journal of Hypertension, 2017, 35, e66.	0.5	1
104	[PP.05.32] PROFOUND SYMPATHETIC NERVOUS SYSTEM ACTIVATION IN PATIENTS WTH RESISTANT HYPERTENSION. Journal of Hypertension, 2017, 35, e127.	0.5	1
105	Renal Denervation And Pulmonary Vein Isolation In Patients With Drug Resistant Hypertension And Symptomatic Atrial Fibrillation. Journal of Atrial Fibrillation, 2014, 7, 1165.	0.5	1
106	Baroreflex Sensitivity. Journal of the American College of Cardiology, 2014, 64, 232-233.	2.8	0
107	Targeting Blood Pressure Lowering and the Sympathetic Nervous System. , 2015, , 287-296.		0
108	Response to Letter to the Editor by Drs. Yang and Yu entitled: Renal denervation in patients with chronic kidney disease. International Journal of Cardiology, 2017, 235, 190.	1.7	0

#	Article	IF	CITATIONS
109	[OP.7A.08] A POLYMORPHISM IN THE NORADRENALINE TRANSPORTER GENE IS ASSOCIATED WITH INCREASED BLOOD PRESSURE IN PATIENTS WITH RESISTANT HYPERTENSION. Journal of Hypertension, 2017, 35, e65.	0.5	0
110	Effects of renal denervation on short-term blood pressure variability. Journal of Hypertension, 2017, 35, 1780-1781.	0.5	0
111	Neural Mechanisms. Updates in Hypertension and Cardiovascular Protection, 2019, , 71-86.	0.1	0
112	Belt and suspenders: Why it pays to protect and cover during carotid stenting. Catheterization and Cardiovascular Interventions, 2020, 96, 128-128.	1.7	0
113	Locally applied chemotherapy is where it's at: New hope in treating infrapopliteal disease. Catheterization and Cardiovascular Interventions, 2020, 96, 402-403.	1.7	0
114	Lithotripsy for peripheral artery disease : Encouraging immediate results…But show us the money!. Catheterization and Cardiovascular Interventions, 2020, 95, 969-970.	1.7	0
115	SYMPATHETIC NERVE ACTIVITY IN SUBJECTS WITH HIGH-NORMAL BLOOD PRESSURE. Journal of Hypertension, 2004, 22, S6.	0.5	0
116	CONTRASTING EFFECTS OF ALCOHOL ON SYMPATHETIC NERVE ACTIVITY IN HEALTHY MIDDLE-AGED VERSUS YOUNG SUBJECTS. Journal of Hypertension, 2004, 22, S18.	0.5	0
117	Smoking, Nicotine and Blood Pressure. , 2012, , 225-235.		0
118	The Role of theÂBrain in Neurogenic Prehypertension. Updates in Hypertension and Cardiovascular Protection, 2019, , 349-360.	0.1	0